Craif presents research results on early detection of pancreatic cancer using microRNA at the 65th Academic Conference of the Japanese Society for Physical Examination and Preventive Medicine
*Craif Co., Ltd.*
Press release: September 20, 2024
**
Craif presents research results on early detection of pancreatic cancer using microRNA at the 65th Academic Conference of the Japanese Society for Physical Examination and Preventive Medicine
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter “Craif”) announced that it will be held at Keio University at the 65th Academic Conference of the Japanese Society for Complete Health Checkups and Preventive Medicine.
Kato, Genomic Medicine Unit, Oncology Center, School of Medicine We are pleased to announce that we have announced the results of our research on pancreatic cancer with Dr. Yoshitaka and others, “Development of a non-invasive liquid biopsy that enables early detection of pancreatic cancer using urinary microRNA.”
Craif will continue to take on the challenge of achieving our company’s mission of “realizing a society where people can live out their natural lives” by widely disseminating new initiatives for cancer prevention and early detection.
* ■Points of this research*
–
Pancreatic cancer is one of the cancers with the highest mortality rate worldwide, with a 5-year survival rate of only about 12%. One reason for this is that early detection is difficult and many patients are diagnosed at an advanced stage.
– Surgery is the definitive treatment, but it is only applied to early-stage cancers, so less than 20% of cases can be treated with surgery.
– In this research, we attempted to develop a new testing method (liquid biopsy) using microRNA in urine to detect early-stage pancreatic cancer.
–
MicroRNAs in urine have some similarities to microRNAs produced by tumors (cancers), and it has been found that they are also related to signals related to pancreatic cancer and the environment around tumors.
– By performing machine learning analysis using microRNA in urine as information, we succeeded in distinguishing pancreatic cancer from healthy people with high accuracy.
– This new testing method uses urine, so it is a next-generation screening method that can be easily performed without putting any strain on the body.
– This test is expected to enable highly accurate early screening for pancreatic cancer, which has been difficult until now.
* ■ About the 65th Japanese Medical Examination and Preventive Medicine Society Academic Conference*
・Holding period: September 6th (Friday) to September 7th (Saturday), 2024 ・Venue: Pacifico Yokohama
・Official homepage: https://www.c-linkage.co.jp/dock65/
* ■ About Craif *
Craif is a venture company founded in 2018 from Nagoya University. NANO is a fundamental technology that detects disease-related biological substances such as microRNA with high precision from easily collected body fluids such as urine.
IP(R)︎ (NANO Intelligence Platform). Craif is NANO
We are working on the development of tests using IP(R)︎ to realize early detection of cancer and medical care tailored to each
individual.
* We have created a new short video to introduce our company. (September 2024)* * Please see the link below for a concise explanation of Craif’s vision and technology. *
*
<
【Company Profile】
Company name: Craif Inc. (pronunciation: Craif, English notation: Craif Inc.) Representative: Representative Director Ryuichi Onose
Established: May 2018
Capital: 100 million yen (as of March 1, 2024)
Business: Research and development of next-generation tests aimed at early detection of diseases and realization of personalized medicine, mainly in the cancer field, and provision of next-generation cancer risk tests “MySignal(R)︎ Series”
Head Office: ITP Hongo Office 5F, 2-25-7 Yushima, Bunkyo-ku, Tokyo URL: https://craif.com/